PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Case Report

Volume 2 Issue 5

Surgical Management of Medullary Thyroid Carcinoma with Retrosternal Extension: A Case Report with Review of Literature

Monalisa Banerjee, Shehnaz Kantharia and Rajesh Kantharia*

October 20, 2023

DOI : 10.56831/PSSRP-02-067


Medullary Thyroid Carcinoma is derived from parafollicular C-cells that normally secretes peptide hormones such as calcitonin, serotonin and vasoactive intestinal peptides and thus it is widely accepted as a neuroendocrine tumor. MTC usually has a good prognosis with a 10 years survival rate of approximately 95.6% in cases restricted to the thyroid gland, but reduces to 40% for those presenting with metastasis. Surgery is considered the primary and best modality of treatment in Medullary Thyroid Carcinoma. Here we present a case of a successful surgical management of a 38 year old female patient of sporadic, medullary thyroid carcinoma with sub sternal extension of the disease.

Keywords: MTC; Sporadic; Total Thyroidectomy; Sub-Sternal Extension


  1. Wells SA Jr., et al. “Revised American Thyroid Association guidelines for the management of Rodrigo Arrangoiz”. American Journal of Otolaryngology and Head and Neck Surgery Remedy Publications 6 (2015): 567-610.
  2. Priya R, Virmani N and Dabholkar JP. “Medullary carcinoma of thyroid: Case report and a review of literature”. Journal of Head & Neck Physicians and Surgeons 4.2 (2016): 80.
  3. Stamatakos M., et al. “Medullary thyroid carcinoma: The third most common thyroid cancer reviewed”. Oncol Lett 2 (2011): 49-53.
  4. Nikiforova MN and Nikiforov YE. “Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis”. Expert Rev Mol Diagn 8.1 (2008): 83-95.
  5. Sippel RS, Kunnimalaiyaan M and Chen H. “Current management of medullary thyroid cancer”. The oncologist 13.5 (2008): 539-47.
  6. Jaquet J. “Ein Fall von metastasierenden Amyloidtumoren (Lymphosarkom)”. Virchows Arch Pathol Anat Physiol 185 (1906): 251-268.
  7. Hazard JB, Hawk WA and Crile G Jr. “Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity”. J Clin Endocrinol Metab 19 (1959): 152-161.
  8. Liu Z., et al. “Antiproliferative effects of Src inhibition on medullary thyroid cancer”. J Clin Endocrinol Metab 89 (2004): 3503-9.
  9. Cakir M and Grossman AB. “Medullary thyroid cancer: Molecular biology and novel molecular therapies”. Neuroendocrinology 90 (2009): 323-48.
  10. de Groot JW., et al. “Determinants of life expectancy in medullary thyroid cancer: Age does not matter”. Clin Endocrinol (Oxf) 65 (2006): 729-36.
  11. Rodrigo Arrangoiz., et al. “Medullary Thyroid Carcinoma Literature Review and Current Management”. J Clin Endocrinal and Diabetes (2018).
  12. Bugalho MJ, Santos JR and Sobrinho L. “Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement”. J Surg Oncol 91.1 (2005): 56-60.
  13. Kudo T., et al. “Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens”. Thyroid 17.7 (2007): 635-8.
  14. Bhanot P., et al. “Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature”. Diagn Cytopathol 35.5 (2007): 285-92.
  15. Jennifer ER., et al. Thyroid - Medullary. American Joint Committee on Cancer Staging Manuel Ed. Amin M. Springer International Publishing.
  16. Gaudin PB and Rosai J. “Florid vascular proliferation associated with neural and neuroendocrine neoplasms. A diagnostic clue and potential pitfall”. Am J Surg Pathol 19.6 (1995): 642-52.
  17. Cohen R., et al. “Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC)”. J Clin Endocrinol Metab 85.2 (2000): 919-22.
  18. Chen H., et al. “The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer”. Pancreas 39.6 (2010): 775-83.
  19. Zenaty D., et al. “Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B”. Eur J Endocrinol 160.5 (2009): 807-13.
  20. Call JA., et al. “A role for radiotherapy in the management of advanced medullary thyroid carcinoma: the mayo clinic experience”. Rare Tumors 5.3 (2013): 37.
  21. Terezakis SA., et al. “Role of external beam radiotherapy in patients with advanced or recurrent nonanaplastic thyroid cancer: Memorial Sloan-kettering Cancer Center experience”. Int J Radiat Oncol Biol Phys 73.3 (2009): 795-801.